Literature DB >> 24655295

Immunology of psoriasis.

Michelle A Lowes1, Mayte Suárez-Fariñas, James G Krueger.   

Abstract

The skin is the front line of defense against insult and injury and contains many epidermal and immune elements that comprise the skin-associated lymphoid tissue (SALT). The reaction of these components to injury allows an effective cutaneous response to restore homeostasis. Psoriasis vulgaris is the best-understood and most accessible human disease that is mediated by T cells and dendritic cells. Inflammatory myeloid dendritic cells release IL-23 and IL-12 to activate IL-17-producing T cells, Th1 cells, and Th22 cells to produce abundant psoriatic cytokines IL-17, IFN-γ, TNF, and IL-22. These cytokines mediate effects on keratinocytes to amplify psoriatic inflammation. Therapeutic studies with anticytokine antibodies have shown the importance of the key cytokines IL-23, TNF, and IL-17 in this process. We discuss the genetic background of psoriasis and its relationship to immune function, specifically genetic mutations, key PSORS loci, single nucleotide polymorphisms, and the skin transcriptome. The association between comorbidities and psoriasis is reviewed by correlating the skin transcriptome and serum proteins. Psoriasis-related cytokine-response pathways are considered in the context of the transcriptome of different mouse models. This approach offers a model for other inflammatory skin and autoimmune diseases.

Entities:  

Mesh:

Year:  2014        PMID: 24655295      PMCID: PMC4229247          DOI: 10.1146/annurev-immunol-032713-120225

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  135 in total

Review 1.  TSLP expression: cellular sources, triggers, and regulatory mechanisms.

Authors:  Toshiro Takai
Journal:  Allergol Int       Date:  2012-01-25       Impact factor: 5.836

2.  Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation.

Authors:  Hideaki Sugiyama; Rolland Gyulai; Eiko Toichi; Edina Garaczi; Shinji Shimada; Seth R Stevens; Thomas S McCormick; Kevin D Cooper
Journal:  J Immunol       Date:  2005-01-01       Impact factor: 5.422

Review 3.  Regulation generation: the suppressive functions of human regulatory T cells.

Authors:  Wendy A Goodman; Kevin D Cooper; Thomas S McCormick
Journal:  Crit Rev Immunol       Date:  2012       Impact factor: 2.214

4.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

5.  Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells.

Authors:  Eynav Klechevsky; Rimpei Morita; Maochang Liu; Yanying Cao; Sebastien Coquery; Luann Thompson-Snipes; Francine Briere; Damien Chaussabel; Gerard Zurawski; A Karolina Palucka; Yoram Reiter; Jacques Banchereau; Hideki Ueno
Journal:  Immunity       Date:  2008-09-19       Impact factor: 31.745

6.  A Toll-like receptor 7, 8, and 9 antagonist inhibits Th1 and Th17 responses and inflammasome activation in a model of IL-23-induced psoriasis.

Authors:  Weiwen Jiang; Fu-Gang Zhu; Lakshmi Bhagat; Dong Yu; Jimmy X Tang; Ekambar R Kandimalla; Nicola La Monica; Sudhir Agrawal
Journal:  J Invest Dermatol       Date:  2013-01-31       Impact factor: 8.551

7.  The psoriatic transcriptome closely resembles that induced by interleukin-1 in cultured keratinocytes: dominance of innate immune responses in psoriasis.

Authors:  John B Mee; Claire M Johnson; Nilesh Morar; Frank Burslem; Richard W Groves
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

8.  Lack of evidence for activation of the hedgehog pathway in psoriasis.

Authors:  Johann E Gudjonsson; Abhishek Aphale; Marina Grachtchouk; Jun Ding; Rajan P Nair; Timothy Wang; John J Voorhees; Andrzej A Dlugosz; James T Elder
Journal:  J Invest Dermatol       Date:  2008-08-28       Impact factor: 8.551

9.  Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis.

Authors:  Mayte Suárez-Fariñas; Katherine Li; Judilyn Fuentes-Duculan; Karen Hayden; Carrie Brodmerkel; James G Krueger
Journal:  J Invest Dermatol       Date:  2012-07-05       Impact factor: 8.551

10.  Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha.

Authors:  Onur Boyman; Hans Peter Hefti; Curdin Conrad; Brian J Nickoloff; Mark Suter; Frank O Nestle
Journal:  J Exp Med       Date:  2004-02-23       Impact factor: 14.307

View more
  431 in total

Review 1.  Immunological Consequences of JAK Inhibition: Friend or Foe?

Authors:  Donal P McLornan; Alesia A Khan; Claire N Harrison
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

2.  Dual Inhibition of PI3K/Akt and mTOR by the Dietary Antioxidant, Delphinidin, Ameliorates Psoriatic Features In Vitro and in an Imiquimod-Induced Psoriasis-Like Disease in Mice.

Authors:  Jean Christopher Chamcheu; Vaqar M Adhami; Stephane Esnault; Mario Sechi; Imtiaz A Siddiqui; Kenneth A Satyshur; Deeba N Syed; Shah-Jahan M Dodwad; Maria-Ines Chaves-Rodriquez; B Jack Longley; Gary S Wood; Hasan Mukhtar
Journal:  Antioxid Redox Signal       Date:  2016-10-04       Impact factor: 8.401

Review 3.  Autoimmunity and autoimmune co-morbidities in psoriasis.

Authors:  Kazuhisa Furue; Takamichi Ito; Gaku Tsuji; Takafumi Kadono; Takeshi Nakahara; Masutaka Furue
Journal:  Immunology       Date:  2018-02-06       Impact factor: 7.397

4.  Psoriasis-Associated Late Cornified Envelope (LCE) Proteins Have Antibacterial Activity.

Authors:  Hanna Niehues; Lam C Tsoi; Danique A van der Krieken; Patrick A M Jansen; Merel A W Oortveld; Diana Rodijk-Olthuis; Ivonne M J J van Vlijmen; Wiljan J A J Hendriks; Richard W Helder; Joke A Bouwstra; Ellen H van den Bogaard; Philip E Stuart; Rajan P Nair; James T Elder; Patrick L J M Zeeuwen; Joost Schalkwijk
Journal:  J Invest Dermatol       Date:  2017-06-17       Impact factor: 8.551

Review 5.  The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

6.  Possible role of BMP-4 in the hyper-pigmentation of psoriatic plaques after anti-TNF-α treatment.

Authors:  Luisa Di Costanzo; Emanuele Scala; Giuseppina Caiazzo; Serena Lembo; Rita Marino; Matteo Megna; Angela Patrì; Roberta Di Caprio; Anna Balato
Journal:  Exp Ther Med       Date:  2019-09-17       Impact factor: 2.447

7.  Non-invasive monitoring of skin inflammation using an oxygen-sensing paint-on bandage.

Authors:  Zongxi Li; Nalu Navarro-Alvarez; Emily J Keeley; Nicholas H Nowell; Beatriz M M Goncalves; Christene A Huang; Conor L Evans
Journal:  Biomed Opt Express       Date:  2017-09-22       Impact factor: 3.732

8.  Dysbiosis and Staphylococcus aureus Colonization Drives Inflammation in Atopic Dermatitis.

Authors:  Tetsuro Kobayashi; Martin Glatz; Keisuke Horiuchi; Hiroshi Kawasaki; Haruhiko Akiyama; Daniel H Kaplan; Heidi H Kong; Masayuki Amagai; Keisuke Nagao
Journal:  Immunity       Date:  2015-04-21       Impact factor: 31.745

9.  Instantaneous depolarization of T cells via dopamine receptors, and inhibition of activated T cells of Psoriasis patients and inflamed human skin, by D1-like receptor agonist: Fenoldopam.

Authors:  Aviad Keren; Amos Gilhar; Yehuda Ullmann; Marina Zlotkin-Frušić; Yoram Soroka; Abraham J Domb; Mia Levite
Journal:  Immunology       Date:  2019-11       Impact factor: 7.397

Review 10.  The role of xenobiotics in triggering psoriasis.

Authors:  Jasna Grželj; Marija Sollner Dolenc
Journal:  Arch Toxicol       Date:  2020-08-24       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.